A unique mouse strain expressing Cre recombinase for tissue‐specific analysis of gene function in palate and kidney development
- 16 October 2007
- Vol. 45 (10), 618-624
- https://doi.org/10.1002/dvg.20334
Abstract
Mammalian palate development is a multistep process, involving initial bilateral downward outgrowth of the palatal shelves from the oral side of the maxillary processes, followed by stage‐specific palatal shelf elevation to the horizontal position above the developing tongue and subsequent fusion of the bilateral palatal shelves at the midline to form the intact roof of the oral cavity. While mutations in many genes have been associated with cleft palate pathogenesis, the molecular mechanisms regulating palatal shelf growth, patterning, and elevation are not well understood. Genetic studies of the molecular mechanisms controlling palate development in mutant mouse models are often complicated by early embryonic lethality or gross craniofacial malformation. We report here the development of a mouse strain for tissue‐specific analysis of gene function in palate development. We inserted an IresCre bicistronic expression cassette into the 3′ untranslated region of the mouse Osr2 gene through gene targeting. We show, upon crossing to the R26R reporter mice, that Cre expression from the Osr2IresCre knockin allele activated β‐galactosidase expression specifically throughout the developing palatal mesenchyme from the onset of palatal shelf outgrowth. In addition, the Osr2IresCre mice display exclusive Cre‐mediated recombination in the glomeruli tissues derived from the metanephric mesenchyme and complete absence of Cre activity in other epithelial and mesenchymal tissues in the developing metanephric kidney. These data indicate that the Osr2IresCre knockin mice provide a unique tool for tissue‐specific studies of the molecular mechanisms regulating palate and kidney development. genesis 45:618–624, 2007.Keywords
This publication has 37 references indexed in Scilit:
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyThe Lancet Oncology, 2012
- Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLCJournal of Thoracic Oncology, 2010
- Long-term survivors of more than 5 years in advanced non-small cell lung cancerLung Cancer, 2010
- Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III StudiesClinical Cancer Research, 2007
- Molecular control of secondary palate developmentDevelopmental Biology, 2007
- The Cellular Basis of Kidney DevelopmentAnnual Review of Cell and Developmental Biology, 2006
- Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinibLung Cancer, 2006
- Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinibLung Cancer, 2005
- Conditional control of gene expression in the mouseNature Reviews Genetics, 2001